BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Djokanovic N, Klieger-Grossmann C, Pupco A, Koren G. Safety of infliximab use during pregnancy. Reprod Toxicol. 2011;32:93-97. [PMID: 21621603 DOI: 10.1016/j.reprotox.2011.05.009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
Number Citing Articles
1 Takayama K, Ishikawa S, Enoki T, Kojima T, Takeuchi M. Successful treatment with infliximab for Behçet disease during pregnancy. Ocul Immunol Inflamm. 2013;21:321-323. [PMID: 23617408 DOI: 10.3109/09273948.2013.781655] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
2 Stiegler JD, Lucas CT, Sami N. Pyoderma gangrenosum in pregnancy successfully treated with infliximab and prednisone. JAAD Case Rep 2017;3:387-9. [PMID: 28879220 DOI: 10.1016/j.jdcr.2017.03.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol 2015;60:575-89. [PMID: 26164735 DOI: 10.1016/j.survophthal.2015.06.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 9.5] [Reference Citation Analysis]
4 Cordero-coma M, Salazar-méndez R, Yilmaz T. Treatment of severe non-infectious uveitis in high-risk conditions (Part I): pregnancy and malignancies, management and safety issues. Expert Opinion on Drug Safety 2015;14:1071-86. [DOI: 10.1517/14740338.2015.1044969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Fasoulakis Z, Antsaklis P, Galanopoulos N, Kontomanolis E. Common Adverse Effects of Anti-TNF Agents on Gestation. Obstet Gynecol Int 2016;2016:8648651. [PMID: 28044081 DOI: 10.1155/2016/8648651] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
6 Bowman CJ, Breslin WJ, Connor AV, Martin PL, Moffat GJ, Sivaraman L, Tornesi MB, Chivers S. Placental Transfer of Fc-Containing Biopharmaceuticals across Species, an Industry Survey Analysis: PLACENTAL TRANSFER OF Fc BIOPHARMACEUTICALS. Birth Defects Res B 2013;98:459-85. [DOI: 10.1002/bdrb.21089] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 5.3] [Reference Citation Analysis]
7 Reinisch W, Van Assche G, Befrits R, Connell W, D'haens G, Ghosh S, Michetti P, Ochsenkühn T, Panaccione R, Schreiber S, Silverberg MS, Sorrentino D, van der Woude CJ, Vermeire S, Panes J. Recommendations for the treatment of ulcerative colitis with infliximab: A gastroenterology expert group consensus. Journal of Crohn's and Colitis 2012;6:248-58. [DOI: 10.1016/j.crohns.2011.11.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
8 Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. Seminars in Arthritis and Rheumatism 2015;45:351-6. [DOI: 10.1016/j.semarthrit.2015.06.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
9 Xu C, Bao S. Behcet's disease and pregnancy-a case report and literature review. Am J Reprod Immunol 2017;77:e12530. [DOI: 10.1111/aji.12530] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 McElwain CJ, McCarthy FP, McCarthy CM. Gestational Diabetes Mellitus and Maternal Immune Dysregulation: What We Know So Far. Int J Mol Sci 2021;22:4261. [PMID: 33923959 DOI: 10.3390/ijms22084261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Malka I, Ziv M. Safety of Common Medications for Treating Dermatology Disorders in Pregnant Women. Curr Derm Rep 2013;2:249-57. [DOI: 10.1007/s13671-013-0062-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
12 Huang VW, Habal FM. From conception to delivery: Managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014; 20(13): 3495-3506 [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
13 Girolomoni G, Altomare G, Ayala F, Berardesca E, Calzavara Pinton P, Chimenti S, Martini P, Peserico A, Puglisi Guerra A, Antonio Vena G; on behalf on the Delphi working group. Differential management of mild-to-severe psoriasis with biologic drugs: An Italian Delphi consensus expert panel. Journal of Dermatological Treatment 2014;26:128-33. [DOI: 10.3109/09546634.2014.907466] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
14 Gisbert JP, Chaparro M. Safety of anti-TNF agents during pregnancy and breastfeeding in women with inflammatory bowel disease. Am J Gastroenterol. 2013;108:1426-1438. [PMID: 23752881 DOI: 10.1038/ajg.2013.171] [Cited by in Crossref: 84] [Cited by in F6Publishing: 78] [Article Influence: 10.5] [Reference Citation Analysis]
15 Ng PY, Ireland DJ, Keelan JA. Drugs to block cytokine signaling for the prevention and treatment of inflammation-induced preterm birth. Front Immunol 2015;6:166. [PMID: 25941525 DOI: 10.3389/fimmu.2015.00166] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 4.5] [Reference Citation Analysis]
16 Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol 2016;2016:6193275. [PMID: 27725926 DOI: 10.1155/2016/6193275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Maleki A, Meese H, Sahawneh H, Foster CS. Progress in the understanding and utilization of biologic response modifiers in the treatment of uveitis. Expert Rev Clin Immunol 2016;12:775-86. [PMID: 26972783 DOI: 10.1586/1744666X.2016.1166052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
18 Amin M, No DJ, Egeberg A, Wu JJ. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say? Am J Clin Dermatol 2018;19:1-13. [PMID: 29080066 DOI: 10.1007/s40257-017-0328-3] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 10.3] [Reference Citation Analysis]
19 Soh MC, Nelson-piercy C. Update of the management of rheumatoid arthritis in pregnancy. Expert Review of Obstetrics & Gynecology 2014;7:77-96. [DOI: 10.1586/eog.11.77] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
20 Ubah OC, Steven J, Porter AJ, Barelle CJ. An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model. Front Immunol 2019;10:526. [PMID: 30967865 DOI: 10.3389/fimmu.2019.00526] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
21 Knickelbein JE, Armbrust KR, Kim M, Sen HN, Nussenblatt RB. Pharmacologic Treatment of Noninfectious Uveitis. Handb Exp Pharmacol 2017;242:231-68. [PMID: 27848029 DOI: 10.1007/164_2016_21] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
22 Orgul G, Aktoz F, Beksac MS. Behcet's disease and pregnancy: what to expect? J Obstet Gynaecol 2018;38:185-8. [PMID: 28816562 DOI: 10.1080/01443615.2017.1336614] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
23 van der Woude CJ, Ardizzone S, Bengtson MB, Fiorino G, Fraser G, Katsanos K, Kolacek S, Juillerat P, Mulders AG, Pedersen N. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124. [PMID: 25602023 DOI: 10.1093/ecco-jcc/jju006] [Cited by in Crossref: 220] [Cited by in F6Publishing: 194] [Article Influence: 44.0] [Reference Citation Analysis]
24 Saha S, Wald A. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf. 2012;11:947-957. [PMID: 22954378 DOI: 10.1517/14740338.2012.720970] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
25 Diav-Citrin O, Otcheretianski-Volodarsky A, Shechtman S, Ornoy A. Pregnancy outcome following gestational exposure to TNF-alpha-inhibitors: a prospective, comparative, observational study. Reprod Toxicol. 2014;43:78-84. [PMID: 24284028 DOI: 10.1016/j.reprotox.2013.11.004] [Cited by in Crossref: 66] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
26 Narula N, Al-dabbagh R, Dhillon A, Sands BE, Marshall JK. Anti-TNFα Therapies Are Safe During Pregnancy in Women with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Inflammatory Bowel Diseases 2014;20:1862-9. [DOI: 10.1097/mib.0000000000000092] [Cited by in Crossref: 51] [Cited by in F6Publishing: 12] [Article Influence: 7.3] [Reference Citation Analysis]
27 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf 2014. [DOI: 10.1517/14740338.2015.973399] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
28 Stone RH, Hong J, Jeong H. Pharmacokinetics of monoclonal antibodies used for inflammatory bowel diseases in pregnant women. J Clin Toxicol 2014;4:209. [PMID: 26539323 DOI: 10.4172/2161-0495.1000209] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
29 Ellinger I, Fuchs R. HFcRn-mediated transplacental immunoglobulin G transport: protection of and threat to the human fetus and newborn. Wien Med Wochenschr 2012;162:207-13. [PMID: 22717875 DOI: 10.1007/s10354-012-0085-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
30 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
31 Habal FM, Huang VW. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther. 2012;35:501-515. [PMID: 22221203 DOI: 10.1111/j.1365-2036.2011.04967.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 4.9] [Reference Citation Analysis]
32 Hoffman MB, Farhangian M, Feldman SR. Psoriasis during pregnancy: characteristics and important management recommendations. Expert Review of Clinical Immunology 2015;11:709-20. [DOI: 10.1586/1744666x.2015.1037742] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
33 Moens A, van Hoeve K, Humblet E, Rahier JF, Bossuyt P, Dewit S, Franchimont D, Macken E, Nijs J, Posen A, Strubbe B, Van Hootegem A, Van Moerkercke W, Vermeire S, Ferrante M; Belgian IBD Research and Development group (BIRD). Outcome of Pregnancies in Female Patients With Inflammatory Bowel Diseases Treated With Vedolizumab. J Crohns Colitis 2019;13:12-8. [PMID: 30281093 DOI: 10.1093/ecco-jcc/jjy142] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 17.0] [Reference Citation Analysis]
34 Ruiz V, Manubens E, Puig L. Psoriasis in pregnancy: a review (II). Actas Dermosifiliogr 2014;105:813-21. [PMID: 24314892 DOI: 10.1016/j.ad.2013.06.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
35 Babuna Kobaner G, Polat Ekinci A. Infliximab for the treatment of recalcitrant generalized pustular psoriasis of pregnancy: Report of a challenging case. Dermatol Ther 2020;33:e13571. [PMID: 32406109 DOI: 10.1111/dth.13571] [Reference Citation Analysis]
36 Khan N, Asim H, Lichtenstein GR. Safety of anti-TNF therapy in inflammatory bowel disease during pregnancy. Expert Opin Drug Saf. 2014;13:1699-1708. [PMID: 25406728 DOI: 10.1517/14740338.2014.973399] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]